215 related articles for article (PubMed ID: 2277297)
1. Low incidence of neoplasia in heart and heart-lung transplant recipients receiving triple-drug immunosuppression.
Olivari MT; Diekmann RA; Kubo SH; Braunlin E; Jamieson SW; Ring WS
J Heart Transplant; 1990; 9(6):618-21. PubMed ID: 2277297
[TBL] [Abstract][Full Text] [Related]
2. Immunosuppressive level and other risk factors for basal cell carcinoma and squamous cell carcinoma in heart transplant recipients.
Fortina AB; Piaserico S; Caforio AL; Abeni D; Alaibac M; Angelini A; Iliceto S; Peserico A
Arch Dermatol; 2004 Sep; 140(9):1079-85. PubMed ID: 15381547
[TBL] [Abstract][Full Text] [Related]
3. Arterial hypertension in heart transplant recipients treated with triple-drug immunosuppressive therapy.
Olivari MT; Antolick A; Ring WS
J Heart Transplant; 1989; 8(1):34-9. PubMed ID: 2647929
[TBL] [Abstract][Full Text] [Related]
4. Five-year experience with triple-drug immunosuppressive therapy in cardiac transplantation.
Olivari MT; Kubo SH; Braunlin EA; Bolman RM; Ring WS
Circulation; 1990 Nov; 82(5 Suppl):IV276-80. PubMed ID: 2225416
[TBL] [Abstract][Full Text] [Related]
5. Non-melanoma skin cancer and its risk factors in an Austrian population of heart transplant recipients receiving induction therapy.
Geusau A; Dunkler D; Messeritsch E; Sandor N; Heidler G; Rödler S; Ankersmit J; Zuckermann A; Tschachler E
Int J Dermatol; 2008 Sep; 47(9):918-25. PubMed ID: 18937654
[TBL] [Abstract][Full Text] [Related]
6. Coronary artery disease in cardiac transplant patients receiving triple-drug immunosuppressive therapy.
Olivari MT; Homans DC; Wilson RF; Kubo SH; Ring WS
Circulation; 1989 Nov; 80(5 Pt 2):III111-5. PubMed ID: 2805289
[TBL] [Abstract][Full Text] [Related]
7. Immunosuppression after heart transplantation: prednisone and cyclosporine with and without azathioprine.
Casale AS; Reitz BA; Greene PS; Augustine S; Baumgartner WA
J Thorac Cardiovasc Surg; 1989 Nov; 98(5 Pt 2):951-5. PubMed ID: 2811426
[TBL] [Abstract][Full Text] [Related]
8. New-onset diabetes mellitus in pediatric thoracic organ recipients receiving tacrolimus-based immunosuppression.
Wagner K; Webber SA; Kurland G; Boyle GJ; Miller SA; Cipriani L; Griffith BP; Fricker FJ
J Heart Lung Transplant; 1997 Mar; 16(3):275-82. PubMed ID: 9087870
[TBL] [Abstract][Full Text] [Related]
9. Effect of early cyclosporine levels on kidney allograft rejection.
Johnson EM; Canafax DM; Gillingham KJ; Humar A; Pandian K; Kerr SR; Najarian JS; Matas AJ
Clin Transplant; 1997 Dec; 11(6):552-7. PubMed ID: 9408683
[TBL] [Abstract][Full Text] [Related]
10. Independent risk factors predicting acute graft rejection in cardiac transplant recipients treated by triple drug immunosuppression.
Laufer G; Miholic J; Laczkovics A; Wollenek G; Holzinger C; Hajek-Rosenmeier A; Wuzl G; Schreiner W; Buxbaum P; Wolner E
J Thorac Cardiovasc Surg; 1989 Dec; 98(6):1113-21. PubMed ID: 2586129
[TBL] [Abstract][Full Text] [Related]
11. Incidence of post-transplant malignancy among 674 solid-organ-transplant recipients at a single center.
Mihalov ML; Gattuso P; Abraham K; Holmes EW; Reddy V
Clin Transplant; 1996 Jun; 10(3):248-55. PubMed ID: 8826661
[TBL] [Abstract][Full Text] [Related]
12. Posttransplant lymphoproliferative disease in thoracic organ transplant patients: ten years of cyclosporine-based immunosuppression.
Armitage JM; Kormos RL; Stuart RS; Fricker FJ; Griffith BP; Nalesnik M; Hardesty RL; Dummer JS
J Heart Lung Transplant; 1991; 10(6):877-86; discussion 886-7. PubMed ID: 1661607
[TBL] [Abstract][Full Text] [Related]
13. Increased incidence of cholelithiasis in heart transplant recipients receiving cyclosporine therapy.
Spes CH; Angermann CE; Beyer RW; Schreiner J; Lehnert P; Kemkes BM; Theisen K
J Heart Transplant; 1990; 9(4):404-7. PubMed ID: 2398436
[TBL] [Abstract][Full Text] [Related]
14. The effects of HLA mismatching and immunosuppressive therapy on early rejection outcome in pediatric heart transplant recipients.
Herzberg GZ; Rossi AF; Courtney M; Gelb BD
J Heart Lung Transplant; 1998 Dec; 17(12):1195-200. PubMed ID: 9883760
[TBL] [Abstract][Full Text] [Related]
15. [Lymphoproliferative syndromes after cardiac transplantation and treatment with cyclosporine. Report of 4 cases].
Guerci AP; Burtin P; Mattei S; Lederlin P
Ann Med Interne (Paris); 1992; 143(3):155-9. PubMed ID: 1524349
[TBL] [Abstract][Full Text] [Related]
16. Annual trends and triple therapy--1991-2000.
Nishikawa K; Terasaki PI
Clin Transpl; 2001; ():247-69. PubMed ID: 12211788
[TBL] [Abstract][Full Text] [Related]
17. De novo cancer in cyclosporine-treated and non-cyclosporine-treated adult primary renal allograft recipients.
Gruber SA; Gillingham K; Sothern RB; Stephanian E; Matas AJ; Dunn DL
Clin Transplant; 1994 Aug; 8(4):388-95. PubMed ID: 7949545
[TBL] [Abstract][Full Text] [Related]
18. Increased rejection in gender-mismatched grafts: amelioration by triple therapy.
Keogh AM; Valantine HA; Hunt SA; Schroeder JS; Oyer PE
J Heart Lung Transplant; 1991; 10(1 Pt 1):106-10. PubMed ID: 2007161
[TBL] [Abstract][Full Text] [Related]
19. Optimum maintenance trough levels of cyclosporine in heart transplant recipients given corticosteroid-free regimen.
Nohria A; Ehtisham J; Ramahi TM
J Heart Lung Transplant; 1998 Sep; 17(9):849-53. PubMed ID: 9773855
[TBL] [Abstract][Full Text] [Related]
20. Malignant tumors after heart transplantation.
Couetil JP; McGoldrick JP; Wallwork J; English TA
J Heart Transplant; 1990; 9(6):622-6. PubMed ID: 2277298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
